Screener
Adaptive Biotechnologies ADPT Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss attributable to Adaptive Biotechnologies Corporation | $(20,033) | $(29,852) |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted | 155,521,048 | 149,195,028 |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted | $(0.13) | $(0.20) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's shares (diluted)?
- Adaptive Biotechnologies (ADPT) reported shares (diluted) of 155.5M in Q1 2026.
- How has Adaptive Biotechnologies's shares (diluted) changed year-over-year?
- Adaptive Biotechnologies's shares (diluted) increased by 4.2% year-over-year, from 149.2M to 155.5M.
- What is the long-term trend for Adaptive Biotechnologies's shares (diluted)?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's shares (diluted) has grown at a 2.4% compound annual growth rate (CAGR), from 560.5M to 616.2M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Adaptive Biotechnologies's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude